CALC CalciMedica
- 5.450
- +0.020+0.37%
CalciMedica News
Express News | HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $20 Price Target
CalciMedica Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 269.69% HC Wainwright & Co. → $20 Reiterates Buy → Buy 04/01/2024 158.78% Oppenheimer $14 → $14
Optimistic Buy Rating for CalciMedica Backed by Strong Financials and Promising Clinical Trials
Express News | CalciMedica Inc: Cash Position Expected to Fund Operations Into 2H 2025
Express News | CalciMedica Q1 2024 GAAP EPS $0.01 Beats $(0.67) Estimate
CalciMedica 1Q EPS 1c >CALC
CalciMedica 1Q EPS 1c >CALC
CalciMedica: Cash Position Expected to Fund Ops Into 2H25 >CALC
CalciMedica: Cash Position Expected to Fund Ops Into 2H25 >CALC
Express News | CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Express News | CalciMedica Q1 Income From Operations USD -5.767 Million
Express News | CalciMedica Q1 Operating Expenses USD 5.767 Million
Express News | CalciMedica Q1 Net Income USD 130 Thousand
Express News | CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Acrivon Therapeutics, Inc. (ACRV) and Viking Therapeutics (VKTX)
CalciMedica Announces Last Patient Enrolled In Phase 2b CARPO Trial Of Auxora In Acute Pancreatitis; Full Target Enrollment Of 216 Patients Achieved
CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the last patient has been enrolled in its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP).
Express News | CalciMedica Inc: Topline Data From Carpo Expected in 2Q 2024
Express News | CalciMedica Inc: Full Target Enrollment of 216 Patients Achieved
Express News | CalciMedica Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora™ in Acute Pancreatitis
CalciMedica And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by around 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
CalciMedica Is Maintained at Outperform by Oppenheimer
CalciMedica Is Maintained at Outperform by Oppenheimer
Top Premarket Decliners
Fractyl Health (GUTS) shares fell 19% Monday premarket after the company reported a wider Q4 net loss. CalciMedica (CALC) shares dropped 18% following a muted session. Vivos Therapeutics (VVOS) shares
Analysis
Price Target
No Data
